Sponsored by the University of Cincinnati
ACPE-accredited and produced by North American Center for Continuing Medical Education, LLC
Target Audience
This activity is designed for emergency physicians, hospitalists, and other physicians and pharmacists involved in the continuum of care.
Learning Objectives
After completing this activity, participants should be able to:
- Recognize the incidence and burden of venous thromboembolism (VTE) in the emergency department through hospital admission and discharge
- Describe the frequent risk factors and comorbidities that increase VTE risk
- Implement updated American College of Chest Physicians guidelines and Joint Commission/National Quality Forum quality measures for VTE prevention and treatment into the continuum of care
- Put into practice current evidence-based nonpharmacologic and pharmacologic options for VTE prophylaxis and treatment to improve outcomes across the continuum of care
Credit Eligibility
To be eligible for documentation of credit, participants must read all monograph content (print or online), log on to www.princetoncme.com to complete the 10-question post-test with a score of 70% or better, and complete the online evaluation form. Participants who successfully complete the posttest and evaluation form online may immediately print their documentation of credit. Please e-mail info@princetoncme.com or call 609-371-1137 if you have questions or need additional information.
Release date: October 3, 2008
Expiration date: October 3, 2009
Estimated time to complete: 3 hours
There is no fee associated with this activity.
CME Accreditation
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Cincinnati designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CPE Accreditation
North American Center for Continuing Medical Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 3 contact hours (0.3 CEUs) of continuing pharmacy education (276-999-08-016-H01-P).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by NACCME may contact John Savage, Director, Medical Education, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535, or jsavage@naccme.com. The Director, Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME, may be made for a second level of review.
Grant Support
Supported by an educational grant from sanofi-aventis U.S.
Participating Faculty
Chair/Cource Director
Franklin A. Michota, MD
Director of Academic Affairs
Department of Hospital Medicine
Cleveland Clinic Foundation
Cleveland, Ohio
Faculty
Charles B. Cairns, MD, FACEP
Professor and Chair
Department of Emergency Medicine
University of North Carolina
School of Medicine
Chapel Hill, North Carolina
Laurie G. Jacobs, MD
Professor of Clinical Medicine
Division Head, Geriatrics
Director, Resnick Gerontology Center
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York
Geno J. Merli, MD
Professor of Medicine
Director
Jefferson Center for Vascular Diseases
Chief Medical Officer
Jefferson Medical College
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Mary Sieggreen, APRN, NP, CVN
Nurse Practitioner
Vascular Surgery
Harper University Hospital
Detroit Medical Center
Detroit, Michigan
Arthur P. Wheeler, MD, FCCP
Associate Professor
Division of Allergy, Pulmonary,
and Critical Care Medicine
Vanderbilt University
Director, Medical ICU
Vanderbilt University Medical Center
Nashville, Tennessee
Ann K. Wittkowsky, PharmD, CACP, FASHP, FCCP
Clinical Professor of Pharmacy
University of Washington
School of Pharmacy
Director of Anticoagulation Services
University of Washington Medical Center
Seattle, Washington
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of the University of Cincinnati and NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Cairns: Research support—GlaxoSmithKline and Response Biomedical Corporation (funds paid to Duke University); Principal Investigator on grants with bioMérieux, Biosite, Heartscape, and Johnson & Johnson (funds paid to Duke University); Consultant—AstraZeneca, bioMérieux, Brahms USA, Inc, Critical Therapeutics, Hutchinson Technology, Sepracor; Speaker—Merck and Co., Inc
Dr. Heit: Research support—Grifols (principal investigator, funds paid to Mayo
Clinic)
Dr. Jacobs: Speakers bureau—sanofi-aventis U.S.
Dr. Merli: Research funding—Bayer Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, sanofi-aventis U.S.; Consultant—Bacchus, Bayer Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals,
sanofi-aventis U.S.; Speakers bureau—Boehringer Ingelheim Pharmaceuticals, sanofi-aventis U.S.
Dr. Michota: Consultant—Medtronic, sanofi-aventis U.S., Scios, Takeda Pharmaceuticals
Dr. Wheeler: Research funding—Novo Nordisk (funds paid to Vanderbilt University); Consultant—Eli Lilly and Company, Pfizer, Inc, sanofi-aventis U.S.; Speakers bureau—Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc, sanofi-aventis U.S.
Dr. Wittkowsky: Consultant—Boehringer Ingelheim Pharmaceuticals, GlaxoSmithKline; Speakers bureau—sanofi-aventis U.S.
Ms. Sieggreen disclosed no relevant financial relationships with any commercial
interests.
Planning Committee Drs. Cairns, Heit, Jacobs, Merli, Michota, Wheeler, and Wittkowsky, and Ms. Sieggreen (see disclosures above); Kay Weigand, University of Cincinnati, and Kristin Dickie, Mary Johnson, Randy Robbin, and John Savage, NACCME, have disclosed they have no relevant financial relationships with any commercial interests.
The University of Cincinnati and NACCME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentations.
The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.
Some of the clinical studies discussed in this activity may have been funded by manufacturers of drugs or devices.
